Monopar Therapeutics (MNPR) Q3 2025 earnings summary

Executive summary

• Clinical-stage biopharma advancing ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals, with multiple clinical and preclinical programs active as of Q3 2025.

• ALXN1840 pivotal Phase 3 met primary endpoint; NDA submission to FDA planned for early 2026.

• Presented new long-term efficacy and safety data for ALXN1840 at major medical conferences, highlighting neurological and hepatic benefits.

• Received FDA clearance for IND application of MNPR-101-Lu for advanced or metastatic solid tumors.

• Recent capital raise in September 2025 netted $91.9 million after share repurchase, extending cash runway through at least December 2027.

Financial highlights

• Cash, cash equivalents, and investments totaled $143.7 million as of September 30, 2025.

• Net loss for Q3 2025 was $3.44 million, compared to $1.30 million in Q3 2024; nine-month net loss was $8.52 million, up from $4.66 million year-over-year.

• R&D expenses rose to $2.59 million in Q3 2025 (up $1.61 million YoY), mainly due to ALXN1840 manufacturing and increased personnel costs.

• G&A expenses increased to $1.50 million in Q3 2025 (up $0.91 million YoY), driven by higher board compensation and personnel costs.

• Interest income increased significantly due to higher cash balances from the capital raise.

Outlook and guidance

• Current funds expected to support operations through at least December 2027, covering NDA submission for ALXN1840 and advancement of radiopharmaceutical pipeline.

• No revenue expected until regulatory approval and commercialization of a product candidate.

• Expenses anticipated to increase as clinical and preclinical programs progress.